Abbott Laboratories vs. ARS Pharmaceuticals, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 8 of 8 compared factors.
Size & Scale
| ABT | SPRY | |
|---|---|---|
| Market Cap | $187.45 billion | $558.89 million |
| Revenue (TTM) | $46.59 billion | $116.93 million |
| Net Income (TTM) | $5.42 billion | $-215,432,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | SPRY | |
|---|---|---|
| P/E Ratio | 35.06 | — |
| Price / Book | 3.62 | 44.67 |
| Price / Sales | 4.02 | 4.78 |
ABT leads on 2 of 2 valuation factors.
Profitability
| ABT | SPRY | |
|---|---|---|
| Net Margin | 11.65% | -184.24% |
| Return on Equity | 10.48% | -1721.80% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | SPRY | |
|---|---|---|
| Dividend Yield | 2.33% | — |
| Payout Ratio | 81.55 | — |
ABT and SPRY split the dividend factors evenly.
Risk & Sentiment
| ABT | SPRY | |
|---|---|---|
| Short Interest | 0.57% | 0.82% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, SPRY overview, SPRY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.